TPC
PHAT icon

Takeda Pharmaceutical Company’s Phathom Pharmaceuticals PHAT Stock Holding History

Takeda Pharmaceutical Company’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,557,063
Closed -$16M – 12
2024
Q2 		$16M Sell
1,557,063
-1,596,154
-51% -$16.4M 6.9% 3
2024
Q1 		$33.5M Sell
3,153,217
-4,306,069
-58% -$36.6M 11.59% 3
2023
Q4 		$77.4M Buy
+7,459,286
New +$64.3M 23.62% 3

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Takeda Pharmaceutical Company's PHAT Position: Q3 2024 in Review

Takeda Pharmaceutical Company sold out of Phathom Pharmaceuticals (PHAT) in Q3 2024, closing a stake of 1,557,063 shares — an estimated $16M sold.

Takeda Pharmaceutical Company first reported a position in PHAT in Q4 2023 and held it in 3 quarters. The position peaked at $77.4M in Q4 2023. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

  • Takeda Pharmaceutical Company reported no remaining Phathom Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Takeda Pharmaceutical Company sold 1,557,063 Phathom Pharmaceuticals shares in Q3 2024, an estimated $16M.
  • Takeda Pharmaceutical Company first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Takeda Pharmaceutical Company's Phathom Pharmaceuticals position peaked at $77.4M in Q4 2023.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2024, filed 13 Feb 2025.